ClinicalTrials.gg

Program

enicepatide

Also written as “Enicepatide” and “CT-388”.

Its studies are mostly in Obesity · Overweight · Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by Hoffmann-La Roche.

Furthest: phase 3, since Jan 16, 202610 company-led studies, 7 open or runningNext primary completion: Apr 8, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche107 open or runningphase 3since Jan 16, 2026Apr 5, 2021Apr 8, 2027phase 1 · NCT07626515
  • Named in Hoffmann-La Roche’s own pipeline as RG6640 enicepatide (CT-388), phase 3, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Zealand Pharma.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 5, 2021First study: phase 1 study in Diabetes MellitusFirst studyNCT04838405 · 129 enrolled · Australia, Mexico
  2. Jul 23, 2024Phase 2 study in ObesityNCT06525935 · 469 enrolled · United States
  3. Oct 3, 2024Phase 2 study in OverweightNCT06628362 · 447 enrolled · United States, Argentina, Canada and more
  4. Jan 16, 20262 phase 3 studies in ObesityPhase 3 reachedNCT07351058, NCT07351045
  5. May 11, 2026Phase 2 study in ObesityNCT07589686 · 486 planned
  6. Jun 1, 2026Phase 1 study in Healthy ParticipantsNCT07626515 · 36 enrolled · China
  7. Jun 22, 2026Phase 3 study in ObesityNCT07670416 · 300 planned · China
  8. Oct 16, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07889648 · 948 planned
  9. Nov 2, 2026Phase 3 study in OverweightNCT07918846 · 8,200 planned

Ahead

  1. Apr 8, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07626515
  2. Nov 12, 2027Primary completion: phase 2 study in ObesityNCT07589686
  3. Feb 24, 2028Primary completion: phase 3 study in ObesityNCT07670416
  4. Jul 24, 2028Primary completion: phase 3 study in ObesityNCT07351045

TargetBeta

“The study will evaluate the efficacy and safety of enicepatide, a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor (GLP-1/GIP) receptor agonist (RA), compared with tirzepatide among participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on o…”study summary, read by Claude · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
TirzepatideruleEli Lillyphase 472
retatrutideruleEli Lillyphase 333
olatorepatideHansoh Pharmaceutical Groupphase 312
UBT251The United Laboratories Internationalphase 312
VK2735ruleViking Therapeuticsphase 38
NNC0519-0130Novo Nordiskphase 211
BI 3034701Boehringer Ingelheimphase 26
HRS-4729Jiangsu HengRui Medicinephase 25
NA-931rulebiomed-industries-incphase 23

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07918846Overweight3Not yet recruitingMar 20, 20318,200
NCT07889648Diabetes Mellitus, Type 23Not yet recruitingApr 2, 2029948
NCT07670416Obesity · China3RecruitingFeb 24, 2028300
NCT07626515Healthy Participants · China1Active, not recruitingApr 8, 202736
NCT07589686Obesity2Not yet recruitingNov 12, 2027486
NCT07351058Obesity · United States, Argentina, Australia and more3RecruitingAug 7, 20281,600
NCT07351045Obesity · United States, Argentina, Australia and more3RecruitingJul 24, 20282,000
NCT06628362Overweight · United States, Argentina, Canada and more2CompletedMay 29, 2026447
NCT06525935Obesity · United States2CompletedDec 8, 2025469
NCT04838405Diabetes Mellitus · Australia, Mexico1CompletedJun 18, 2024129

How it is read

Names in the registry

  • “Enicepatide”, 9 entries
  • “CT-388”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.